• Explore the evolution of AI from task-focused tools to foundation and agentic systems transforming drug discovery and development • Gain practical strategies for building scalable, compliant, and effective AI solutions that accelerate R&D outcomes
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
Key Takeaways:
Steve Worland, Ph.D. serves as the CEO of Numerion Labs and has over 30 years of experience in corporate leadership and pharmaceutical R&D. He was previously President, CEO, and Board Member of eFFECTOR Therapeutics, which he co-founded in 2012. Prior to that, he was CEO of Anadys Pharmaceuticals, where he led the company through its acquisition by Roche in 2011. Before becoming CEO, he served as Chief Scientific Officer and President of Pharmaceuticals at Anadys.
Earlier in his career, he held senior positions at Agouron Pharmaceuticals, Warner-Lambert, and Pfizer, where his scientific research contributed to the discovery and development of Paxlovid (nirmatrelvir), Inlyta (axitinib), zotatifin, tomivosertib, and other clinical-stage candidates. At Agouron, he was Vice President and Director of Molecular Biology and Biochemistry, remaining at the company through its acquisitions.
Dr. Worland earned a Ph.D. in Chemistry from the University of California, Berkeley, and completed a postdoctoral fellowship in Molecular Biology at Harvard University as an NIH fellow. He earned a B.S. with Highest Honors in Biological Chemistry from the University of Michigan. He serves on the Board of Directors at Blacksmith Medicines and has previously served on the boards of Tracon Pharmaceuticals, Forge Therapeutics, and GenMark Diagnostics.
Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge ML technologies. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
